AU2001294549A1 - Process and intermediates - Google Patents
Process and intermediatesInfo
- Publication number
- AU2001294549A1 AU2001294549A1 AU2001294549A AU9454901A AU2001294549A1 AU 2001294549 A1 AU2001294549 A1 AU 2001294549A1 AU 2001294549 A AU2001294549 A AU 2001294549A AU 9454901 A AU9454901 A AU 9454901A AU 2001294549 A1 AU2001294549 A1 AU 2001294549A1
- Authority
- AU
- Australia
- Prior art keywords
- intermediates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
- C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23178400P | 2000-09-12 | 2000-09-12 | |
| US60231784 | 2000-09-12 | ||
| PCT/US2001/028443 WO2002022554A1 (en) | 2000-09-12 | 2001-09-12 | Process and intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001294549A1 true AU2001294549A1 (en) | 2002-03-26 |
Family
ID=22870636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001294549A Abandoned AU2001294549A1 (en) | 2000-09-12 | 2001-09-12 | Process and intermediates |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6570024B2 (en) |
| EP (1) | EP1322597B1 (en) |
| JP (1) | JP4886961B2 (en) |
| AR (1) | AR030612A1 (en) |
| AT (1) | ATE555078T1 (en) |
| AU (1) | AU2001294549A1 (en) |
| CY (1) | CY1112871T1 (en) |
| DK (1) | DK1322597T3 (en) |
| ES (1) | ES2383792T3 (en) |
| PT (1) | PT1322597E (en) |
| WO (1) | WO2002022554A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| WO2002092771A2 (en) | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
| EA013323B1 (en) * | 2004-12-09 | 2010-04-30 | Сентокор, Инк. | Anti-integrin immunoconjugates, methods and uses |
| MX2009007987A (en) | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease. |
| US9023356B2 (en) | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
| JP5532486B2 (en) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Monoclonal antibody 175 targeting EGF receptor and derivatives and uses thereof |
| PL2437785T3 (en) | 2009-06-04 | 2015-08-31 | Novartis Ag | METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION |
| JP2012531212A (en) | 2009-07-03 | 2012-12-10 | アビペップ ピーティーワイ リミテッド | Immunoconjugate and method for producing the same |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| SG181814A1 (en) | 2009-12-23 | 2012-07-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
| AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| CN114246952A (en) | 2010-06-08 | 2022-03-29 | 基因泰克公司 | Cysteine engineered antibodies and conjugates |
| RS64791B1 (en) | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - binding proteins |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| AU2014348552A1 (en) | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
| KR20170052600A (en) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | Cysteine engineered antibodies and conjugates |
| US11420981B2 (en) * | 2019-04-18 | 2022-08-23 | Indena S.P.A. | Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof |
| WO2022248870A1 (en) | 2021-05-28 | 2022-12-01 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
| CA3233953A1 (en) | 2021-10-05 | 2023-04-13 | Matthew Bruce | Combination therapies for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE430062B (en) * | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | COUPLING OR TIOLATION REAGENTS |
| JPS61112042A (en) * | 1985-07-31 | 1986-05-30 | Wakunaga Seiyaku Kk | Compound suitable as crosslinking reagent |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| JP3408158B2 (en) * | 1998-07-17 | 2003-05-19 | 大日本製薬株式会社 | Sultopride derivatives and anti-sultopride antibodies |
| US6573074B2 (en) * | 2000-04-12 | 2003-06-03 | Smithkline Beecham Plc | Methods for ansamitocin production |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
-
2001
- 2001-09-05 AR ARP010104219A patent/AR030612A1/en unknown
- 2001-09-12 JP JP2002526755A patent/JP4886961B2/en not_active Expired - Fee Related
- 2001-09-12 PT PT01975197T patent/PT1322597E/en unknown
- 2001-09-12 AU AU2001294549A patent/AU2001294549A1/en not_active Abandoned
- 2001-09-12 WO PCT/US2001/028443 patent/WO2002022554A1/en active Application Filing
- 2001-09-12 US US10/009,381 patent/US6570024B2/en not_active Expired - Lifetime
- 2001-09-12 AT AT01975197T patent/ATE555078T1/en active
- 2001-09-12 ES ES01975197T patent/ES2383792T3/en not_active Expired - Lifetime
- 2001-09-12 DK DK01975197.3T patent/DK1322597T3/en active
- 2001-09-12 EP EP01975197A patent/EP1322597B1/en not_active Expired - Lifetime
-
2003
- 2003-03-17 US US10/390,252 patent/US6884874B2/en not_active Expired - Lifetime
-
2012
- 2012-06-15 CY CY20121100548T patent/CY1112871T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2383792T3 (en) | 2012-06-26 |
| WO2002022554A1 (en) | 2002-03-21 |
| AR030612A1 (en) | 2003-08-27 |
| US20020156318A1 (en) | 2002-10-24 |
| EP1322597A4 (en) | 2005-10-19 |
| PT1322597E (en) | 2012-06-01 |
| US20040014980A1 (en) | 2004-01-22 |
| JP2004509094A (en) | 2004-03-25 |
| JP4886961B2 (en) | 2012-02-29 |
| EP1322597B1 (en) | 2012-04-25 |
| CY1112871T1 (en) | 2016-04-13 |
| EP1322597A1 (en) | 2003-07-02 |
| DK1322597T3 (en) | 2012-07-02 |
| US6884874B2 (en) | 2005-04-26 |
| ATE555078T1 (en) | 2012-05-15 |
| US6570024B2 (en) | 2003-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001294549A1 (en) | Process and intermediates | |
| AU2001252973A1 (en) | Biosensor and related method | |
| AU2001280599A1 (en) | Compounds and methods | |
| AU2001253418A1 (en) | Compounds and methods | |
| EG23373A (en) | Process and intermediates. | |
| AU2002220932A1 (en) | Chemical process and new intermediates | |
| AU2001243394A1 (en) | Compounds and methods | |
| AU2001281965A1 (en) | Novel 6-phenylphenanthridines | |
| AU2001292936A1 (en) | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines | |
| AU2001244470A1 (en) | Assembly process | |
| GB0123961D0 (en) | Process and intermediates | |
| AU2001295185A1 (en) | Multiplexing-interleaving and demultiplexing-deinterleaving | |
| AUPQ872300A0 (en) | Compounds and methods | |
| AU2001236718A1 (en) | Bioreactor and related method | |
| AU2002218440A1 (en) | New process | |
| AU2001278951A1 (en) | Compounds and methods | |
| AU2001272757A1 (en) | Process for producing 5-fluorooxyindole and for producing intermediate therefor | |
| AU2001237530A1 (en) | Method | |
| AU2001266176A1 (en) | Methods | |
| AU2001210572A1 (en) | Ornament | |
| AU2001241636A1 (en) | Halotherapy method | |
| AU2001267769A1 (en) | Process | |
| AU2002256556A1 (en) | Sea-trosy and related methods | |
| AU2002235277A1 (en) | Compounds and methods | |
| AU2001250536A1 (en) | Methods |